|224.09||-9.45||-4.05%||Vol 5.61M||1Y Perf 55.26%|
|Jun 11th, 2021 16:02 DELAYED|
|- -||- -%|
|Target Price||208.82||Analyst Rating||Moderate Buy 1.67|
|Potential %||-6.81||Finscreener Ranking||★★ 45.76|
|Insiders Trans % 3/6/12 mo.||100/100/-43||Value Ranking||★+ 44.78|
|Insiders Value % 3/6/12 mo.||100/100/-93||Growth Ranking||★★★+ 56.83|
|Insiders Shares Cnt. % 3/6/12 mo.||100/100/-93||Income Ranking||★+ 36.02|
|Market Cap||214.91B||Earnings Rating||Sell|
|Price Range Ratio 52W %||88.97||Earnings Date||29th Jul 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||29th Jul 2021|
|Estimated EPS Next Report||1.90|
|EPS Growth Next 5 Years %||14.60|
|Avg. Weekly Volume||7.40M|
|Avg. Monthly Volume||4.17M|
|Avg. Quarterly Volume||3.68M|
Eli Lilly and Company (NYSE: LLY) stock closed at 224.09 per share at the end of the most recent trading day (a -4.05% change compared to the prior day closing price) with a volume of 5.64M shares and market capitalization of 214.91B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 19500 people. Eli Lilly and Company CEO is David A. Ricks.
The one-year performance of Eli Lilly and Company stock is 55.26%, while year-to-date (YTD) performance is 32.72%. LLY stock has a five-year performance of 204.96%. Its 52-week range is between 129.21 and 235.85, which gives LLY stock a 52-week price range ratio of 88.97%
Eli Lilly and Company currently has a PE ratio of 30.20, a price-to-book (PB) ratio of 28.08, a price-to-sale (PS) ratio of 8.37, a price to cashflow ratio of 23.60, a PEG ratio of 2.32, a ROA of 13.46%, a ROC of 29.39% and a ROE of 119.77%. The company’s profit margin is 23.87%, its EBITDA margin is 34.50%, and its revenue ttm is $25.49 Billion , which makes it $26.57 revenue per share.
Of the last four earnings reports from Eli Lilly and Company, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $1.90 for the next earnings report. Eli Lilly and Company’s next earnings report date is 29th Jul 2021.
The consensus rating of Wall Street analysts for Eli Lilly and Company is Moderate Buy (1.67), with a target price of $208.82, which is -6.81% compared to the current price. The earnings rating for Eli Lilly and Company stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Eli Lilly and Company has a dividend yield of 1.53% with a dividend per share of $3.40 and a payout ratio of 43.00%.
Eli Lilly and Company has a Buy technical analysis rating based on Technical Indicators (ADX : 16.36, ATR14 : 6.55, CCI20 : 140.10, Chaikin Money Flow : 0.10, MACD : 8.17, Money Flow Index : 70.40, ROC : 12.48, RSI : 69.35, STOCH (14,3) : 70.86, STOCH RSI : 0.22, UO : 58.97, Williams %R : -29.15), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Eli Lilly and Company in the last 12-months were: Aarti S. Shah (Option Excercise at a value of $0), Alfonso G. Zulueta (Option Excercise at a value of $0), Alfonso G. Zulueta (Sold 28 000 shares of value $4 640 000 ), Anat Hakim (Option Excercise at a value of $0), David A. Ricks (Option Excercise at a value of $0), Jackson P. Tai (Buy at a value of $249 759), Johna L. Norton (Option Excercise at a value of $0), Joshua Smiley (Option Excercise at a value of $0), Leigh Ann Pusey (Option Excercise at a value of $0), Melissa S. Barnes (Option Excercise at a value of $0), Melissa S. Barnes (Sold 5 000 shares of value $755 050 ), Michael B. Mason (Option Excercise at a value of $0), Michael Mason (Option Excercise at a value of $0), Myles O'Neill (Option Excercise at a value of $0), Stephen Fry (Option Excercise at a value of $0), Stephen Fry (Sold 7 204 shares of value $1 085 210 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.